Drug General Information
Drug ID
D02AAO
Former ID
DIB014475
Drug Name
AZD-4877
Synonyms
Anticancer therapeutic (solid tumors), AstraZeneca
Drug Type
Small molecular drug
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 2 [522297], [542683]
Company
AstraZeneca plc
Structure
Download
2D MOL

3D MOL

Formula
C28H33N5O2S
InChI
InChI=1S/C28H33N5O2S/c1-18(2)24(32(16-8-15-29)27(34)22-13-11-19(3)12-14-22)25-30-26-23(20(4)31-36-26)28(35)33(25)17-21-9-6-5-7-10-21/h5-7,9-14,18,24H,8,15-17,29H2,1-4H3
InChIKey
SMFXSYMLJDHGIE-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Kinesin-like protein KIF11 Target Info Inhibitor [531974]
Reactome MHC class II antigen presentation
Kinesins
WikiPathways MHC class II antigen presentation
Kinesins
References
Ref 522297ClinicalTrials.gov (NCT00661609) A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer. U.S. National Institutes of Health.
Ref 542683(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7708).
Ref 531974Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.